TY - JOUR T1 - Evaluating the Uric Acid/Albumin Ratio as a Biomarker for Disease Severity in Acute Myocarditis Patients TT - Akut Miyokardit Hastalarında Ürik Asit/Albümin Oranının Hastalık Şiddetinin Biyobelirteci Olarak Değerlendirilmesi AU - Eyiol, Hatice AU - Eyiol, Azmi AU - Şahin, Ahmet Taha PY - 2025 DA - October Y2 - 2025 DO - 10.54005/geneltip.1677988 JF - Genel Tıp Dergisi JO - Genel Tıp Derg PB - Selçuk Üniversitesi WT - DergiPark SN - 2602-3741 SP - 922 EP - 933 VL - 35 IS - 5 LA - en AB - ABSTRACTAim Uric acid/albumin ratio (UAR) has recently emerged as a potential marker for oxidative stress and inflammation, which are key components in the pathophysiology of myocarditis. Therefore, high UAR may reflect increased disease activity and severity in myocarditis patients. In this study, we aimed to evaluate the usability of uric acid/albumin ratio as a biomarker in determining disease severity in patients with acute myocarditis.Methods The study population was evaluated retrospectively. Laboratory parameters of the patients were examined. We classified the condition as severe myocarditis based on the presence of refractory chest pain, hypotension, detection of pericardial effusion with subsequent increase, a decrease in ejection fraction (EF), and lack of response to medical and symptomatic treatment. The primary outcome was the association between UAR and disease severity.Results The median age was 43.5 years. The UAR was significantly higher in females (0.10 vs. 0.10, p=0.003). Patients with pericardial effusion had significantly higher UARs (0.137 vs. 0.100, p KW - Myocarditis KW - Uric Acid/Albumin Ratio KW - Pericardial Effusion N2 - ÖZAmaç: Ürik asit/albümin oranı (UAR), miyokarditin patofizyolojisinde anahtar bileşenler olan oksidatif stres ve inflamasyon için potansiyel bir belirteç olarak son zamanlarda ortaya çıkmıştır. Bu nedenle yüksek UAR, miyokardit hastalarında artan hastalık aktivitesini ve şiddetini yansıtabilir. Bu çalışmada akut miyokarditli hastalarda hastalık şiddetini belirlemede ürik asit/albümin oranının biyobelirteç olarak kullanılabilirliğini değerlendirmeyi amaçladık.Gereç ve Yöntemler: Çalışma popülasyonu retrospektif olarak değerlendirildi. Hastaların laboratuvar parametreleri incelendi. Dirençli göğüs ağrısı, hipotansiyon, perikardiyal efüzyonun saptanması ve ardından artış olması, ejeksiyon fraksiyonunda (EF) azalma ve tıbbi ve semptomatik tedaviye yanıt olmaması nedeniyle durumu şiddetli miyokardit olarak sınıflandırdık. Birincil sonuç, UAR ile hastalık şiddeti arasındaki ilişkiydi.Bulgular: Ortalama yaş 43.5 idi. UAR kadınlarda anlamlı derecede yüksekti (0.10’a karşı 0.10, p=0.003). Perikardiyal efüzyonlu hastalarda UAR'lar anlamlı derecede yüksekti (0.137'ye karşı 0.100, p CR - 1. Ammirati E, Moslehi JJ. Diagnosis and Treatment of Acute Myocarditis: A Review. JAMA 2023; 329(13):1098-1113 CR - 2. Ammirati E, Veronese G, Bottiroli M, Wang DW, Cipriani M, Garascia A, et al. Update on acute myocarditis. Trends Cardiovasc Med 2021; 31(6):370-379 CR - 3. Lampejo T, Durkin SM, Bhatt N, Guttmann O. Acute myocarditis: aetiology, diagnosis and management. Clin Med (Lond) 2021; 21(5):e505-e510 CR - 4. Golpour A, Patriki D, Hanson PJ, McManus B, Heidecker B. Epidemiological Impact of Myocarditis. J Clin Med 2021; 10(4) CR - 5. Rroku A, Kottwitz J, Heidecker B. Update on myocarditis - what we know so far and where we may be heading. Eur Heart J Acute Cardiovasc Care 2021; 10(4):455-467 CR - 6. Basso C. Myocarditis. N Engl J Med 2022; 387(16):1488-1500 CR - 7. Tschope C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol 2021; 18(3):169-193 CR - 8. Kim HW, Jenista ER, Wendell DC, Azevedo CF, Campbell MJ, Darty SN, et al. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol 2021; 6(10):1196-1201 CR - 9. Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and Pericarditis After Vaccination for COVID-19. JAMA 2021; 326(12):1210-1212 CR - 10. Ozgur Y, Akin S, Yilmaz NG, Gucun M, Keskin O. Uric acid albumin ratio as a predictive marker of short-term mortality in patients with acute kidney injury. Clin Exp Emerg Med 2021; 8(2):82-88 CR - 11. Kalkan S, Cagan Efe S, Karagoz A, Zeren G, Yilmaz MF, Simsek B, et al. A New Predictor of Mortality in ST-Elevation Myocardial Infarction: The Uric Acid Albumin Ratio. Angiology 2022; 73(5):461-469 CR - 12. Yalcinkaya D, Karacali K, Ilhan BC, Yarlioglues M. Relation Between Serum Uric Acid to Albumin Ratio and Severity of Chronic Coronary Artery Disease. Angiology 2024; 75(4):386-393 CR - 13. Cerik IB, Dindas F, Koyun E, Dereli S, Sahin A, Turgut OO, et al. New prognostic markers in pulmonary arterial hypertension: CRP to albumin ratio and uric acid Clin Biochem. 2022; 100:22-28 CR - 14. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol 2018; 72(24):3158-3176 CR - 15. Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, Sabe MA, et al. Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association. Circulation 2020; 141(6):e69-e92 CR - 16. McCarthy RE, 3rd, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000; 342(10):690-695 CR - 17. Ammirati E, Cipriani M, Lilliu M, Sormani P, Varrenti M, Raineri C, et al. Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis. Circulation 2017; 136(6):529-545 CR - 18. Ammirati E, Veronese G, Brambatti M, Merlo M, Cipriani M, Potena L, et al. Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction. J Am Coll Cardiol 2019; 74(3):299-311 CR - 19. Cooper LT, Jr., Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC, et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008; 102(11):1535-1539 CR - 20. Kandolin R, Lehtonen J, Salmenkivi K, Raisanen-Sokolowski A, Lommi J, Kupari M. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail 2013; 6(1):15-22 CR - 21. Mahfoud F, Gartner B, Kindermann M, Ukena C, Gadomski K, Klingel K, et al. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J 2011; 32(7):897-903 CR - 22. Merlo M, Ammirati E, Gentile P, Artico J, Cannata A, Finocchiaro G, et al. Persistent left ventricular dysfunction after acute lymphocytic myocarditis: Frequency and predictors. PLoS One 2019; 14(3):e0214616 CR - 23. Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, et al. Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. J Am Coll Cardiol 2020; 75(5):467-478 CR - 24. Prenner SB, Pillutla R, Yenigalla S, Gaddam S, Lee J, Obeid MJ, et al. Serum Albumin Is a Marker of Myocardial Fibrosis, Adverse Pulsatile Aortic Hemodynamics, and Prognosis in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc 2020; 9(3):e014716 CR - 25. Tade G, Hsu HC, Woodiwiss AJ, Peters F, Robinson C, Dlongolo N, et al. Uric Acid, Ferritin, Albumin, Parathyroid Hormone and Gamma-Glutamyl Transferase Concentrations are Associated with Uremic Cardiomyopathy Characteristics in Non-Dialysis and Dialysis Chronic Kidney Disease Patients. Int J Nephrol Renovasc Dis 2022; 15:353-369 UR - https://doi.org/10.54005/geneltip.1677988 L1 - https://dergipark.org.tr/tr/download/article-file/4781423 ER -